OTSUKA PHARMACEUTICAL CO., LTD.
🇯🇵Japan
- Country
- 🇯🇵Japan
- Ownership
- Public, Subsidiary
- Established
- 1964-01-01
- Employees
- 101
- Market Cap
- -
- Website
- http://www.otsuka.co.jp
Exploratory Study of OPC-12759 Ophthalmic Suspension
Phase 2
Completed
- Conditions
- Keratoconjunctival Epithelial Disorder
- Interventions
- First Posted Date
- 2011-12-15
- Last Posted Date
- 2015-03-10
- Lead Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Target Recruit Count
- 102
- Registration Number
- NCT01493180
- Locations
- 🇯🇵
Kansai Region, Kobe, Japan
🇯🇵Chugoku region, Kure, Japan
🇯🇵Tokai region, Nagoya, Japan
Study of OCV-501 in Patients With Acute Myeloid Leukemia (AML) (Extension From Study 311-10-001)
- First Posted Date
- 2011-11-21
- Last Posted Date
- 2021-03-02
- Lead Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Target Recruit Count
- 18
- Registration Number
- NCT01475370
- Locations
- 🇯🇵
National Cancer Center, Tokyo, Japan
Safety Study of OPC-12759 Ophthalmic Solution
Phase 1
Completed
- Conditions
- Dry Eye Syndromes
- Interventions
- Drug: OPC-12759 Ophthalmic solution
- First Posted Date
- 2011-11-11
- Last Posted Date
- 2021-06-29
- Lead Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Target Recruit Count
- 100
- Registration Number
- NCT01471093
- Locations
- 🇯🇵
Kansai region, Osaka, Japan
A Long-term Trial of OPC-34712 in Patients With Schizophrenia
- First Posted Date
- 2011-10-21
- Last Posted Date
- 2019-12-30
- Lead Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Target Recruit Count
- 282
- Registration Number
- NCT01456897
A Dose-finding Trial of OPC-34712 in Patients With Schizophrenia
- First Posted Date
- 2011-10-13
- Last Posted Date
- 2019-10-03
- Lead Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Target Recruit Count
- 459
- Registration Number
- NCT01451164
A Phase I Study of OCV-501 in Acute Myeloid Leukemia Patients
- First Posted Date
- 2011-09-27
- Last Posted Date
- 2021-03-08
- Lead Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Target Recruit Count
- 9
- Registration Number
- NCT01440920
- Locations
- 🇯🇵
National Cancer Center, Tokyo, Japan
Effect of Tolvaptan on Mid- to Long-term Prognosis of Heart Failure Patients
- First Posted Date
- 2011-09-22
- Last Posted Date
- 2019-10-22
- Lead Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Target Recruit Count
- 100
- Registration Number
- NCT01439009
Phase I/II Study of OPB-31121 in Patients With Progressive Hepatocellular Carcinoma
Phase 1
Completed
- Conditions
- Hepatocellular Carcinoma
- Interventions
- Drug: OPB-31121 phase2
- First Posted Date
- 2011-08-01
- Last Posted Date
- 2015-06-08
- Lead Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Target Recruit Count
- 23
- Registration Number
- NCT01406574
Phase I Study of OPB-51602 in Patients With Hematologic Malignancies
Phase 1
Completed
- Conditions
- Multiple MyelomaNon-Hodgkin LymphomaAcute Myeloid LeukemiaAcute Lymphoid LeukemiaChronic Myeloid Leukemia
- Interventions
- First Posted Date
- 2011-04-29
- Last Posted Date
- 2015-06-08
- Lead Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Target Recruit Count
- 20
- Registration Number
- NCT01344876
A Study to Investigate the Long-term Safety and Efficacy of Tolvaptan in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) [Extension of Trial 156-04-251 in Japan]
Phase 3
Completed
- Conditions
- Autosomal Dominant Polycystic Kidney Disease （ADPKD)
- Interventions
- First Posted Date
- 2011-01-21
- Last Posted Date
- 2019-01-17
- Lead Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Target Recruit Count
- 135
- Registration Number
- NCT01280721
© Copyright 2025. All Rights Reserved by MedPath